Aligos Therapeutics, Inc. (ALGS)
ALGSNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$2.21
-0.3600 (-14.01%) today
Regular session, Nov 11, 10:07 AM ET
- Market cap
- $13.81m
- P/E
- –
- EPS, last 4 quarters
- $-6.35
- Dividend yield
- –
- Day range
- $2.18 to $2.81
- 52-week range
- $2.56 to $13.69
- Average volume
- 45.0k
- Previous close
- $2.57
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $50.00, +2162.4% from here
Earnings
next estimate $-2.03Next report
Dec 2025
+8.6%
Mar 2026
+3.5%
Jun 2026
+90.1%
Sep 2026
+14.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $741.0k | $169.0k | $2.83m | $27.78m |
| Gross profit | $741.0k | $169.0k | $2.83m | $27.78m |
| Operating income | -$28.36m | -$21.81m | -$26.93m | -$1.89m |
| Net income | -$31.54m | -$19.88m | -$23.04m | -$1.50m |
Last four quarters: revenue $31.52m, margin -241.0%, free cash flow -$94.52m
News
8 latest- Aligos Therapeutics, Inc. Reports Third Quarter 2026 Financial ResultsFintel · 5 days ago
- Aligos Therapeutics To Present HBV, HDV Programs At AASLD 2026 RTTNews · Oct 6, 2026
- Aligos Therapeutics Jumps 28% As Pevifoscorvir Advances Toward 2027 Phase 2 Data RTTNews · Aug 10, 2026
- Aligos Completes Enrollment In Phase 2 Trial Of Pevifoscorvir Sodium For HBV; Stock Down RTTNews · Jul 13, 2026
- Aligos Secures $25M Upfront In Greater China HBV Deal; Stock Up RTTNews · Jul 7, 2026
- Lake Street Initiates Coverage of Aligos Therapeutics (ALGS) with Buy RecommendationFintel · May 28, 2026
- Aligos Presents Promising Data For Pevifoscovir Sodium In Treating Hepatitis B RTTNews · May 27, 2026
- Cantor Fitzgerald Initiates Coverage of Aligos Therapeutics (ALGS) with Overweight RecommendationFintel · May 21, 2026
The company
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- aligos.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.